Sirio Pharma Co., Ltd. (300791.SZ)
- Previous Close
24.26 - Open
29.00 - Bid 23.72 x --
- Ask 23.73 x --
- Day's Range
23.15 - 24.03 - 52 Week Range
16.32 - 27.29 - Volume
5,024,792 - Avg. Volume
5,533,927 - Market Cap (intraday)
7.301B - Beta (5Y Monthly) 0.90
- PE Ratio (TTM)
21.74 - EPS (TTM)
1.09 - Earnings Date --
- Forward Dividend & Yield 0.50 (2.06%)
- Ex-Dividend Date May 27, 2025
- 1y Target Est
25.49
Sirio Pharma Co., Ltd. operates as a contract manufacturer for dietary supplement industry worldwide. The company develops and manufactures a range of softgel dietary supplements; vegetarian softgel; nutritious gummies; probiotic balls; tablet and powder products; capsules; and functional beverages. It also offers a range of services, including primary and final packaging. Sirio Pharma Co., Ltd. was founded in 1993 and is based in Shantou, China.
www.siriopharma.com2,776
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: 300791.SZ
View MorePerformance Overview: 300791.SZ
Trailing total returns as of 5/29/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 300791.SZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 300791.SZ
View MoreValuation Measures
Market Cap
7.17B
Enterprise Value
8.09B
Trailing P/E
21.34
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.67
Price/Book (mrq)
2.77
Enterprise Value/Revenue
1.92
Enterprise Value/EBITDA
20.36
Financial Highlights
Profitability and Income Statement
Profit Margin
7.85%
Return on Assets (ttm)
4.90%
Return on Equity (ttm)
9.87%
Revenue (ttm)
4.21B
Net Income Avi to Common (ttm)
330.67M
Diluted EPS (ttm)
1.09
Balance Sheet and Cash Flow
Total Cash (mrq)
691.84M
Total Debt/Equity (mrq)
57.30%
Levered Free Cash Flow (ttm)
342.62M